Author

Amanda Hoerres

Observed institution: C4 Therapeutics (United States)

OpenAlex ID: A5085543239

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.

2024 · Marcus Smith Noel, Kurt C. Demel, et al. · Journal of Clinical Oncology · 13

Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

2022 · Sagar Lonial, Shambavi Richard, et al. · Cancer Research · 11

751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor

2023 · David Sommerhalder, Marcus Noel, et al. · Regular and Young Investigator Award Abstracts · 3

Works count: 3

Citation count: 27

H-index: 3

I10-index: 2